Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGN1703 and Ipilimumab in Advanced Solid Malignancies
NCT02668770Phase 1Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2016
- Primary completion
- Nov 2025
- Modality
- Antisense DNA, Prophylactic Vaccines, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label trial of lefitolimod in cancer and melanoma (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 84 days. Started May 2016; status: terminated.
02
Drugs
lefitolimod
03
Conditions
cancermelanoma
Beyond the preview
Go deeper on NCT02668770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02668770.